Company: TAK
Filing Date: 2025-10-30
Form Type: 6-K
Source: 0001395064-25-000152
Chunk: 29

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-10-30
Form: 6-K
Chunk 29
---
 |     |     |        — |
| Acquisition of treasury shares                                                                |     |                                      |   -1,882 |     |     |  -51,603 |
| Interest paid                                                                                 |     |                                      |  -42,298 |     |     |  -52,296 |
| Dividends paid                                                                                |     |                                      | -147,309 |     |     | -154,082 |
| Repayments of lease liabilities                                                               |     |                                      |  -23,375 |     |     |  -22,318 |
| Other, net                                                                                    |     |                                      |   -9,120 |     |     |   -5,476 |
| Net cash from (used in) financing activities                                                  |     |                                      |  206,336 |     |     | -226,881 |
| Net increase in cash and cash equivalents                                                     |     |                                      |  425,779 |     |     |  285,444 |
| Cash and cash equivalents at the beginning of the year                                        |     |                                      |  457,800 |     |     |  385,113 |
| Effects of exchange rate changes on cash and cash equivalents                                 |     |                                      |  -24,564 |     |     |   10,929 |
| Cash and cash equivalents at the end of the period                                            |     |                                      |  859,015 |     |     |  681,486 |

<div align='center'>22</div>

Takeda Pharmaceutical Company Limited (4502)

Earnings Report ( Kessan Tanshin ) for the Six-month

Period Ended September 30, 2025 (Consolidated)

(6) Notes to Condensed Interim Consolidated Financial Statements

(Significant Uncertainty Regarding Going Concern Assumption)

Not applicable.

(Material Accounting Policies)

Material accounting policies adopted for the condensed interim consolidated financial statements are the same as those adopted for the consolidated financial statements as of and for the fiscal year ended March 31, 2025.

Takeda calculated income tax expenses for the six-month period ended September 30, 2025, based on the estimated average annual effective tax rate.

(Operating Segment Information)

Takeda comprises a single operating segment and is engaged in the research, development, manufacturing, marketing and out-licensing of pharmaceutical products. This is consistent with how the financial information is viewed in allocating resources, measuring performance, and forecasting future periods by the CEO who is Taked